HUC-MSCs treatment not checked
Shenzhen Beike Bio-Technology Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Double dosing is selected by the investigators and the sponsor based on the data from the single-dose part of the study. One superior dose is chosen for multiple dosing (tentatively set at 3E6 cells/kg, administered twice with an interval of 4 weeks; the actual dose, frequency and interval of multiple dosing can be adjusted according to the available data). During the trial, stable standard…”In the company’s words, NCT07041801 on ClinicalTrials.gov
- Tested for
- Systemic Lupus Erythematosus (SLE)
- Main trialPhase 1/2
- “This study will investigate the safety and efficacy of allogeneic umbilical cord-derived stem cell therapy in treating patients with moderate to severe systemic lupus erythematosus.”In the company’s words, NCT07041801 on ClinicalTrials.gov
- Other names
- MSC-medium · MSC-high
Other drugs for Systemic Lupus Erythematosus (SLE)
- CenerimodViatris Innovation GmbH · Phase 3
- IanalumabNovartis · Phase 3
- UpadacitinibAbbVie · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- Dapirolizumab pegolUCB Biopharma SRL · Phase 3
- Mycophenolate mofetilRoche · Phase 3
Coming up1
- 5 Sep 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 5 Sep 2027 | Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026